Donald G. Musson

About

Donald G. Musson is a leading figure in bioanalytical chemistry, specializing in the development of high-performance liquid chromatography (HPLC) and tandem mass spectrometry (MS/MS) methods for drug quantification in biological matrices. His major contributions center on advancing automated, high-throughput sample preparation and detection techniques to improve the reliability and sensitivity of pharmacokinetic studies. Notably, his most cited work (43 citations) presents a robust method using high turbulence liquid chromatography (HTLC) online extraction with MS/MS for the simultaneous determination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and its two metabolites in human serum—a critical tool for cancer therapy monitoring. Musson also pioneered a modified HPLC method for ertapenem in urine, enhancing selectivity and automation (14 citations), and developed an automated enzyme inhibition assay for atorvastatin-derived HMG-CoA reductase inhibitors in plasma using radioactivity detection (9 citations). His work has significantly streamlined drug analysis, reducing manual steps and improving accuracy, thereby supporting clinical trials and therapeutic drug monitoring. Musson’s methods remain foundational in pharmaceutical bioanalysis, reflecting his enduring impact on the field.

Research Focus

Key Achievements

Top Papers

1. 1
   High turbulence liquid chromatography online extraction and tandem mass spectrometry for the simultaneous determination of suberoylanilide hydroxamic acid and its two metabolites in human serum

   43 citations · 2005
2. 2
   Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation

   14 citations · 2002
3. 3
   Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection

   9 citations · 2007

Key Collaborators

Contact & Links